文献速递乳腺MR

动态增强MRI背景实质强化在预测乳腺癌复发风险中的评估

Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk.
PubMed 文献 · Radiology · 2024-01-01

本研究为回顾性单机构研究,纳入2007年1月至2012年1月(开发集127例)及2012年1月至2017年1月(内部测试集60例)确诊乳腺癌的女性患者,采用计算机算法定量测量双乳背景实质强化(BPE),并以Oncotype DX复发评分为参考标准。结果显示双乳BPE测量与高风险Oncotype DX复发评分相关(比值比范围1.27-1.66,95%CI 1.02-2.56,P<.001至P=.04),BPE联合肿瘤放射组学特征区分高风险与低/中风险评分的AUC在开发集为0.94、测试集为0.79。

要点

  • 双乳定量BPE测量与Oncotype DX高风险复发评分相关,比值比范围1.27-1.66(95%CI 1.02-2.56,P<.001至P=.04)。
  • BPE联合肿瘤放射组学模型区分高风险与低/中风险Oncotype DX评分的AUC在开发集为0.94、测试集为0.79。
  • 联合模型预测实际远处复发的阴性预测值为0.97,预测局部复发的阴性预测值为0.93。

核心结论

  • 乳腺癌患者同侧和对侧DCE MRI定量BPE测量有助于区分高复发风险与低或中复发风险患者,效果与Oncotype DX复发评分相似。

研究设计与样本

  • HIPAA合规的回顾性单机构研究,开发集纳入2007年1月至2012年1月确诊乳腺癌的女性127例(平均年龄58岁±10.2[标准差];高风险33例,低或中风险94例),内部测试集纳入2012年1月至2017年1月确诊的女性60例(平均年龄57.8岁±11.6;高风险16例,低或中风险44例);采用院内开发的计算机算法自动定量双乳BPE;以Oncotype DX复发评分二分类(高风险>25,低或中风险≤25)为参考标准。

诊断标准与关键数值

  • BPE测量以Oncotype DX复发评分二分类为参考:高风险为复发评分>25,低或中风险为复发评分≤25;双乳BPE测量与高风险评分相关,比值比范围1.27-1.66(95%CI 1.02-2.56;P<.001至P=.04);BPE联合肿瘤放射组学模型区分高风险与低或中风险评分的AUC在开发集为0.94、测试集为0.79;联合模型预测实际远处复发的阴性预测值为0.97、预测局部复发的阴性预测值为0.93;开发集实际局部或远处复发率为15.7%(20/127),随访至少10年。

临床应用与阅片要点

  • 原文结论指出,乳腺癌患者同侧和对侧DCE MRI定量BPE测量可帮助区分高复发风险与低或中复发风险患者,效果与Oncotype DX复发评分相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Background parenchymal enhancement (BPE) at dynamic contrast-enhanced (DCE) MRI of cancer-free breasts increases the risk of developing breast cancer; implications of quantitative BPE in ipsilateral breasts with breast cancer are largely unexplored. Purpose To determine whether quantitative BPE measurements in one or both breasts could be used to predict recurrence risk in women with breast cancer, using the Oncotype DX recurrence score as the reference standard. Materials and Methods This HIPAA-compliant retrospective single-institution study included women diagnosed with breast cancer between January 2007 and January 2012 (development set) and between January 2012 and January 2017 (internal test set). Quantitative BPE was automatically computed using an in-house-developed computer algorithm in both breasts. Univariable logistic regression was used to examine the association of BPE with Oncotype DX recurrence score binarized into high-risk (recurrence score >25) and low- or intermediate-risk (recurrence score ≤25) categories. Models including BPE measures were assessed for their ability to distinguish patients with high risk versus those with low or intermediate risk and the actual recurrence outcome. Results The development set included 127 women (mean age, 58 years ± 10.2 [SD]; 33 with high risk and 94 with low or intermediate risk) with an actual local or distant recurrence rate of 15.7% (20 of 127) at a minimum 10 years of follow-up. The test set included 60 women (mean age, 57.8 years ± 11.6; 16 with high risk and 44 with low or intermediate risk). BPE measurements quantified in both breasts were associated with increased odds of a high-risk Oncotype DX recurrence score (odds ratio range, 1.27-1.66 [95% CI: 1.02, 2.56]; P < .001 to P = .04). Measures of BPE combined with tumor radiomics helped distinguish patients with a high-risk Oncotype DX recurrence score from those with a low- or intermediate-risk score, with an area under the receiver operating characteristic curve of 0.94 in the development set and 0.79 in the test set. For the combined models, the negative predictive values were 0.97 and 0.93 in predicting actual distant recurrence and local recurrence, respectively. Conclusion Ipsilateral and contralateral DCE MRI measures of BPE quantified in patients with breast cancer can help distinguish patients with high recurrence risk from those with low or intermediate recurrence risk, similar to Oncotype DX recurrence score. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Zhou and Rahbar in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Arefan D, Zuley ML, Berg WA, et al. Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk. Radiology. 2024. PMID: 38259203. doi:10.1148/radiol.230269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。